Secures $3.2m in PIPE Financing -- $50m Term Sheet Obtained for Available Financing under Equity Line of Credit - BOSTON and ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

BioNTech has signed a definitive agreement to acquire Biotheus to obtain complete worldwide rights to BNT327/PM8002, a ...

Leerink Partners analyst Jeffrey La Rosa has maintained their bullish stance on PYXS stock, giving a Buy rating yesterday. Jeffrey La Rosa has ...

Jonathan Chang, an analyst from Leerink Partners, reiterated the Buy rating on Vincerx Pharma Inc (VINC – Research Report). The ...

AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US ...

PDS Biotech's lead investigational targeted immunotherapy Versamune ® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination ...